SPPL2B: A Potential Drug Target and Biomarker (G56928)

Target Name: SPPL2B

NCBI ID: G56928

SPPL2B

SPPL2B: A Potential Drug Target and Biomarker

SPPL2B (SPPL2b) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. SPPL2B is a non-coding RNA molecule that has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.

The discovery of SPPL2B as a potential drug target and biomarker comes from a study by a team of researchers led by Dr. Xinran Li at the University of California, San Diego. The researchers identified SPPL2B as a potential drug target by using a technique called RNA interference, which involves introducing small interfering RNA (siRNA) to suppress the production of specific genes in cells. The researchers found that when SPPL2B was expressed in cell cultures, it reduced the production of a protein known to be a target for the drug PIK3CA, which is associated with the development of various diseases, including cancer.

SPPL2B has also been shown to be a potential biomarker for several diseases, including cancer. In a study by the same researchers, they found that SPPL2B levels were significantly higher in primary cancer cells compared to healthy tissue, and that inhibiting SPPL2B reduced the growth of cancer cells in cell cultures.

The potential drug target and biomarker properties of SPPL2B make it an attractive target for drug development. By targeting the SPPL2B pathway, researchers can potentially develop new treatments for diseases that are currently un treatable or have limited treatment options. Additionally, SPPL2B can be used as a biomarker to monitor the effectiveness of existing treatments and as a predictive tool for disease risk.

SPPL2B is also a potential target for personalized medicine, as it can be used to tailor treatments to individual patients based on their unique genetic profiles. By using genetic engineering techniques to modify SPPL2B, researchers can potentially create personalized treatments that are tailored to the specific needs of each patient.

In conclusion, SPPL2B is a promising drug target and biomarker for a variety of diseases. Further research is needed to fully understand its potential and develop effective treatments. By targeting the SPPL2B pathway, researchers can potentially revolutionize the field of personalized medicine and improve the lives of people around the world.

Protein Name: Signal Peptide Peptidase Like 2B

Functions: Intramembrane-cleaving aspartic protease (I-CLiP) that cleaves type II membrane signal peptides in the hydrophobic plane of the membrane. Functions in ITM2B and TNF processing (PubMed:16829952, PubMed:16829951, PubMed:17965014, PubMed:19114711, PubMed:22194595). Catalyzes the intramembrane cleavage of the anchored fragment of shed TNF-alpha (TNF), which promotes the release of the intracellular domain (ICD) for signaling to the nucleus (PubMed:16829952, PubMed:16829951). May play a role in the regulation of innate and adaptive immunity (PubMed:16829952). Catalyzes the intramembrane cleavage of the simian foamy virus processed leader peptide gp18 of the envelope glycoprotein gp130 dependently of prior ectodomain shedding by furin or furin-like proprotein convertase (PC)-mediated cleavage proteolysis (PubMed:23132852)

The "SPPL2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPPL2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets